By Joe Woelfel

Stocks traded mostly higher Tuesday in the last trading session of a year that has seen double-digit gains for each of the three major Wall Street indexes.

These stocks were making moves Tuesday:

Super Micro Computer was up 0.9% after the artificial-intelligence server maker fell 4.1%, making it Monday's worst performer in the S&P 500. The volatile stock, up 7.9% in 2024 heading into Tuesday, has limped into year-end.

Shares of Boeing were up 0.3%. The aerospace giant declined 2.3% on Monday following a deadly plane crash in South Korea. The plane, operated by South Korea's Jeju Air, was a twin-engine Boeing 737-800 that was manufactured in 2009.

Nvidia was falling 0.8%. It was the only stock of the 30 in the Dow Jones Industrial Average that finished higher on Monday, closing with a gain of 0.4%. Entering Tuesday's session, Nvidia has gained 178% this year.

Broadcom fell 0.6%. The stock closed down 2.6% on Monday as investors took profits in shares of the semiconductor and software company that has gained 111% in 2024.

Tesla shares slipped 0.2% after falling for three-straight sessions. The electric-vehicle maker is expected to release fourth-quarter deliveries this week, likely Thursday.

MicroStrategy rose 1.4%, a day after shares of the world's largest corporate holder of Bitcoin fell 8.2% following a disclosure that the company's weekly purchases of the cryptocurrency again declined from the prior week. MicroStrategy has sold stock and used the proceeds to buy Bitcoin for eight straight weeks.

Palantir Technologies, the top stock in the S&P 500 this year with a gain of nearly 350%, was down 1.2%.

VeriSign rose 0.7% after Warren Buffett's Berkshire Hathaway bought almost $16 million more in shares of the internet domain-name registry company, adding to its stake. Berkshire Hathaway is the largest shareholder of VeriSign, with a stake of more than 10%.

Sangamo Therapeutics declined 53% to $1.11 after announcing that its agreement with Pfizer on gene therapy for hemophilia A will end April 21, 2025. Sangamo said Pfizer won't be proceeding with plans to submit the treatment for approval or marketing giroctocogene fitelparvovec.

Write to Joe Woelfel at joseph.woelfel@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

December 31, 2024 09:45 ET (14:45 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.